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Abstract
Macrophage inhibitory cytokine-1 (MIC-1/GDF15), a divergent member of the TGF-b superfamily, is over-expressed by many
common cancers including those of the prostate (PCa) and its expression is linked to cancer outcome. We have evaluated
the effect of MIC-1/GDF15 overexpression on PCa development and spread in the TRAMP transgenic model of spontaneous
prostate cancer. TRAMP mice were crossed with MIC-1/GDF15 overexpressing mice (MIC-1fms) to produce syngeneic
TRAMPfmsmic-1 mice. Survival rate, prostate tumor size, histopathological grades and extent of distant organ metastases were
compared. Metastasis of TC1-T5, an androgen independent TRAMP cell line that lacks MIC-1/GDF15 expression, was
compared by injecting intravenously into MIC-1fms and syngeneic C57BL/6 mice. Whilst TRAMPfmsmic-1 survived on average
7.4 weeks longer, had significantly smaller genitourinary (GU) tumors and lower PCa histopathological grades than TRAMP
mice, more of these mice developed distant organ metastases. Additionally, a higher number of TC1-T5 lung tumor colonies
were observed in MIC-1fms mice than syngeneic WT C57BL/6 mice. Our studies strongly suggest that MIC-1/GDF15 has
complex actions on tumor behavior: it limits local tumor growth but may with advancing disease, promote metastases. As
MIC-1/GDF15 is induced by all cancer treatments and metastasis is the major cause of cancer treatment failure and cancer
deaths, these results, if applicable to humans, may have a direct impact on patient care.
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Introduction
Prostate cancer (PCa) is the most commonly diagnosed cancer
in men after skin cancer and is the second leading cause of male
cancer deaths. In 2011, in the USA alone, there were 240,890 new
cases of PCa and approximately 33,720 deaths [1]. PCa, like many
cancers, is characterized by the altered expression of cytokines and
growth factors. One such cytokine is MIC-1/GDF15, a divergent
member of the transforming growth factor-b (TGF-b) superfamily
[2] that is over-expressed by many patients with common cancers
including those of the prostate and can be further induced by
cancer therapies including surgery, chemo and radio-therapy of
prostate, colon and breast cancer [3–9].
MIC-1/GDF15 protein expression is markedly enhanced in
cancer tissues, and cancer cell lines. In cancers, such as that of the
prostate, the major source of MIC-1/GDF15 is the malignant
epithelial cell itself [5,10], although there may also be a
contribution from tumor stromal cells [11] and infiltrating
phagocytes [12]. This tumor expression of MIC-1/GDF15 is
often reflected in its blood levels, which increase with cancer
development and progression [5,10,13–27], generally in propor-
tion to the stage and extent of disease. For example, serum levels
rise progressively in patients from normal, to low-grade colonic
polyps, high-grade colonic polyps, localized colon cancer and
finally disseminated colon cancer [13]. Patients with colon cancer
who have elevated serum MIC-1/GDF15 levels have a worse
overall prognosis and earlier disease relapse [13,25]. Similar results
have been observed for many other malignancies including
melanoma [28,29] and cancers of the pancreas [12,19,30], thyroid
[31,32], ovary [26] and endometrium [27]. In prostate cancer
patients, serum MIC-1/GDF15 concentrations independently
predict bone metastasis and overall survival [14,21].
In patients with advanced cancers, serum MIC-1/GDF15 levels
rise from an average in non-cancer patients of about 450 pg/ml
[13] to up to 10,000–100,000 pg/ml [5]. Because of its effects on
feeding centres within the brain, elevation in serum levels of MIC-
1/GDF15 is an important cause of cancer-associated anorexia/
cachexia [33]. The amount of MIC-1/GDF15 present in serum of
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cancer patients is, in part, dependent on the proportion of MIC-1/
GDF15 localized to the tumor versus that diffusing into the
circulation [34]. The variable processing of MIC-1/GDF15 results
in secretion in both an unprocessed (with propeptide) and a
processed (without propeptide) form [34]. As its propeptide
domain binds to extracellular matrix, unprocessed MIC-1/
GDF15 remains localized to the tumor stroma, whilst the
processed form rapidly diffuses into the circulation [12,34]. In
PCa, an increased amount of MIC-1/GDF15 localized to the
tumor improves patient outcome, especially in those with a
Gleason sum score of 6 or less [34].
Although there are multiple lines of evidence linking MIC-1/
GDF15 to cancer in general and PCa specifically, convincing and
consistent data on its biological role in the pathogenesis and
progression of cancer is limited [4]. Evidence, largely from in vitro
and xenograft experiments provide apparently contradictory
results. The majority of studies have suggested that MIC-1/
GDF15 has anticancer activity and induces tumor cell apoptosis
[35–38]. For example, MIC-1/GDF15 transfected HCT-116,
human colorectal cancer cells exhibited increased basal apoptosis,
increased response to non-steroid anti-inflammatory drugs and
reduced soft agar cloning efficiency [35]. The DU145 PCa cell
line, one of the few that does not express MIC-1/GDF15,
undergoes apoptosis when treated in vitro with MIC-1/GDF15
[36].
Contradicting the above data, there is also evidence from in vitro
experiments that MIC-1/GDF15 may facilitate tumor progression
[39–42]. For example, enforced MIC-1/GDF15 overexpression or
treatment with purified recombinant MIC-1/GDF15 significantly
increased the in vitro invasion of gastric cancer cell lines. This was
mediated by an increase in urokinase type-plasminogen-activator
(uPA) and involved activation of extracellular signal regulated
kinase-1/2 (ERK-1/2) [16]. Overexpression and knockdown
experiments in androgen-dependent LNCaP-C33 human PCa
cell line and its highly metastatic variant, androgen-independent
LNCaP-LN3 have shown that MIC-1/GDF15 can promote the
proliferation of androgen receptor (AR+)-positive LNCaP cells via
the stimulation of the ERK-1/2 signal pathway [20]. By contrast,
others have not been able to identify any action of MIC-1/GDF15
on the in vitro proliferation of LNCaP cells [36].
The in vivo cancer related activity of MIC-1/GDF15, has also
been examined in a limited number of tumor xenograft studies.
Enforced MIC-1/GDF15 overexpression in HCT-116 colon
cancer cells, xenografted into nude mice, resulted in reduction in
tumor size [35]. A glioblastoma cell line, with no antiproliferative
response to MIC-1/GDF15 in vitro, failed to grow as a tumor
xenograft in nude mice when transfected with MIC-1/GDF15
[43]. In contrast, siRNA knock down of MIC-1/GDF15 in a
melanoma cell line significantly reduced the growth of xenografted
tumors [28].
Because MIC-1/GDF15 is so frequently and substantially
overexpressed in cancers, and because anti-cancer treatments
induce MIC-1/GDF15 expression both in cancer and non-cancer
tissues, any effects on tumor behavior may be of high clinical
significance. In order to obtain the most reliable data on the
overall role of MIC-1/GDF15 in the biology of PCa, and by
analogy cancer in general, we utilised Transgenic Adenocarcinoma
ofMouse Prostate (TRAMP) prostate cancer prone mice. TRAMP
mice express SV40 early genes (T and t; Tag) in the prostatic
epithelium under the control of rat probasin (rPB) promoter [44].
Heterozygous TRAMP male mice develop progressive prostate
cancer exhibiting the spectrum of disease as it occurs in men that is
invasive and capable of metastatic spread to distant sites, primarily
the pelvic lymph nodes, liver, kidney and lungs [45]. We crossed
TRAMP mice with MIC-1/GDF15 overexpressing mice (MIC-
1fms) to produce TRAMP mice that overexpress MIC-1/GDF15
(TRAMPfmsmic-1). In MIC-1fms mice expression of MIC-1/GDF15
is from myeloid cells (macrophages, dendritic cells and neutro-
phils), and is sufficient to increase its serum levels by about 10–90
fold [33]. We have compared survival rate, pattern of PCa growth
and spread in TRAMP and TRAMPfmsmic-1 mice. These studies
demonstrate that whilst TRAMPfmsmic-1 mice have more slowly
growing tumors, survive about 1/3 longer and have lower grade
tumors, they develop much more metastases. Therefore, like TGF-
b, MIC-1/GDF15 has a complex effect on tumor behavior,
inhibiting local tumor growth, but enhancing metastatic spread.
Materials and Methods
Ethics Statement
All research and animal care procedures were approved by the
Garvan Institute/St Vincent’s Hospital Animal Experimentation
Ethics Committee (Ethics No: 07/05 and 10/05) and were in
agreement with the Australian Code of Practice for the Care and
Use of Animals for Scientific Purpose.
Transgenic Mice
MaleTRAMPmice heterozygous for the PB-Tag transgene, were
generated by mating TRAMP+/2 females (C57BL/6 background)
with non-transgenicC57BL/6males. InTRAMPmice, theminimal
ratprobasin (rPB)regulatorysequencetargetsSV40earlygene (Tand
t; Tag) expression specifically to prostatic epithelium [44]. Syngeneic
mice overexpressing MIC-1/GDF15 under control of the myeloid
cell specific c-fms promoter (MIC-1fms) were used to breed TRAMP
mice that also overexpress MIC-1/GDF15 (TRAMPfmsmic-1). MIC-
1/GDF15 expression in MIC-1fms mice is from myeloid cells, but is
sufficient to also increase its serum levels by about 10–90 fold [33].
The double transgenic TRAMPfmsmic-1 mice were generated by
crossing TRAMP+/2 females with homozygous MIC-1fms males.
The PB-SV40 T transgene was identified using DNA extracted
from tail samples and PCR primers directed at the PB-SV40 T
antigen sequence: Pb-forward: 59-CCGGTCGACCG-
GAAGCTTCCACAAGTGCATTTA-39 and SV40Tag-reverse:
59-CTCCTTTCAAGACCTAGAAGGTCCA-39. PCR was per-
formed using reaction mixture and conditions described previously
[46]. The MIC-1/GDF15 transgene in TRAMPfmsmic-1 mice was
identified by PCR using primers, Flag-forward: 59-GACTA-
CAAGGACGACGATGACAAG-39 and MS8-reverse: 59-
CGAAGCCTACCGCGTGCACCGAG-39 and reaction condi-
tions: denaturation at 95uC for 10 s, annealing at 60uC for 20 s,
and extension at 72uC for 30 s.
Survival Study
Based on the statistical power analysis for sample size, 35
TRAMP and 35 TRAMPfmsmic-1 mice were allocated at 4–
6 weeks of age, for a survival study. From that time, mice were
weighed once a week and monitored twice a week for tumor size
and extent by palpating the abdomen. Mice either died or were
culled when they reached ethical end points of tumor size larger
than 11 mm611 mm611 mm, more than 20% weight loss or
meeting any other ethical end point criteria for euthanasia. The
overall survival of individual mice was calculated from birth to
ethical end point or death from tumor. Survival distribution was
estimated using the method of Kaplan-Meier. At necropsy the
genitourinary complex (GU) consisting of prostate (including
dorsal, lateral, ventral, and anterior lobes), urethra, ampullary
gland, seminal vesicle (SV) and urinary bladder was taken out and
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weighed. Weight of the GU, prostate, and SV of each mouse was
normalized by its body weight (organ wt/body wt).
Primary Tumor Size
In a separate cohort to that above, GU and prostate tumor
growth was compared in TRAMP and TRAMPfmsmic-1 mice. At
the start of the study 60 TRAMP and 60 TRAMPfmsmic-1 mice, 15
of each for each stage, were pre-allocated to be sacrificed at
different time points from early to advanced tumor stages (8, 17,
25 and 33 weeks of age). An additional 3 mice were assigned to the
TRAMP, 33-week group as 3 of the original mice in this group
died or reached ethical end points between 23 and 33 weeks of
age. For each of the 60 mice necropsied, the GU was excised.
Total GU, prostate and seminal vesicle weight were measured and
prostatic dimensions recorded. All measurements were normalized
for the donor mouse total body weight. After this, the tissue was
used for prostate tumor grading.
Prostate Tumor Grading
Prostate tissues from 8, 17, 25 and 33 weeks old TRAMP and
TRAMPfmsmic-1 mice above, were placed in a cassette and fixed in
10% neutral buffered formalin. Care was taken to place and
embed prostates from all the mice in this experiment in the same
orientation. Sections were taken at 200-mm intervals until the
tissue in the block was exhausted. Slides were stained with
haematoxylin and eosin and all the sections for individual animals
were examined using light microscopy, by a histopathologist
experienced in prostate pathology. The histopathologist was
blinded as to the genotype of the mice from where the tumor
originated. The tissues sections were graded using the criteria of
Gingrich et al [47]. Briefly, (a) normal epithelium was assigned a
score of 1; (b) low grade prostatic intraepithelial neoplasia (PIN)
with tufting of the epithelium and increased nucleus to cytoplasm
ratio were scored as 2; (c) high grade PIN with noted cribiform
structures and an increase in mitotic and/or apoptotic figures was
scored as 3; (d) well-differentiated adenocarcinoma with the loss of
interductal spaces and the invasion of basement membranes was
scored as 4; (e) moderately-differentiated adenocarcinoma with
total loss of ductal lumens with evidence of adenocarcinoma was
scored as 5; and (f) poorly-differentiated adenocarcinoma with
sheets of anaplastic cells were scored as 6. Each section from each
mouse was graded and the proportion of the prostate affected by
each grade was estimated. The data from all sections in a given
mouse were pooled to provide an average proportion of the
prostate affected by each prostate cancer grade.
Identification of Tumor Metastases
We estimated the occurrence of metastasis at the time of death
or culling in survival group TRAMP and TRAMPfmsmic-1 mice. At
the necropsy pelvic lymph nodes, kidney, liver and rectal tumors (if
present) were harvested and fixed in 10% neutral buffered
formalin. Lungs were excised, weighed and fixed in Bouin’s
fixative (Sigma-Aldrich) to visualize and count lung tumor
colonies. Metastatic lesions on all the organs were counted under
a dissecting microscope. Some of the lesions were confirmed by
H&E staining and further by immunostaining of frozen tissue
sections with anti Tag antibody (Santa Cruz) to confirm the
prostatic origin of the tumor.
To ensure the accuracy of metastasis data obtained from the
survival group mice, we examined a further cohort of TRAMP
(n= 59) and TRAMPfmsmic-1 (n = 33) mice. In this group, we
determined the proportion of mice with metastasis that died
between 18–40 weeks, a period where TRAMP and TRAMPfms-
mic-1 mice reach ethical end points at the same rate.
Evaluation of MIC-1/GDF15 Expression by qRT-PCR
MIC-1/GDF15 expression in prostates of 8, 17 and 25 weeks
TRAMP (n= 5) and TRAMPfmsmic-1 (n = 5) mice was determined
by qRT-PCR and normalized to B-actin (house keeping gene)
expression. Samples were collected and placed immediately into
1 ml of RNAlater (Qiagen) for storage at 220uC until extraction.
RNA was extracted using Trizol (Invitrogen) and Ambion Purelink
RNA Mini Kit (Invitrogen) with on column DNase step performed
using RNA-Free DNase Set (Qiagen). AMV reverse transcriptase
(Roche Applied Sciences) was used to perform reverse transcrip-
tion on 2 mg of RNA from each sample. The specific primers for
PCR for mouse MIC-1/GDF15 were, Forward: 59-AGGACTC-
GATCAGAACCAAG-39 and Reverse: 59-CGGTTGACGCG-
GAGTAGCA-39 and for B-actin were Forward: 59-TGACAG-
GATGCAGAAGGAGATTACTG-39 and Reverse: 59-
CCACCGATCCACACAGAGTACTTG-39. Diluted cDNA
samples (1:10) were subjected to PCR amplification with
25 mM MgCl2 (Roche Applied Sciences), Taq polymerase (Roche
Applied Sciences) and SYBR Green I dye (Invitrogen). qRT-PCR
was performed on Lightcycler LC480 instrument (Roche Applied
Sciences). The reaction mixture was denatured at 95uC for 10 s,
followed by 60 to 67uC annealing for 15 s, and extension at 72uC
for 20 s. The specificity of the products was verified by melting
curves generated by the Lightcycler 480 software version 1.5 and
by PCR product size on electrophoretic gels. Gene copy numbers
for both MIC-1/GDF15 and B-actin were calculated by making
standard curves generated by amplifying serially diluted MIC-1/
GDF15 and B-actin PCR products. Cp values of samples were
determined using second derivative calculations performed by
Lightcycler 480 software version 1.5. MIC-1/GDF15 copy
numbers were normalized to B-actin copy number.
Relative MIC-1/GDF15 expression in TC1-T5 cell line was also
estimated by qRT-PCR and compared with that in advanced
TRAMP and TRAMPfmsmic-1 prostate tumors. TC1-T5 cells were
grown in six well plates as below. RNA from TC1-T5 cells (n = 3)
was extracted using RNeasy Mini Kit (Qiagen). RNA from
TRAMP (n= 3) and TRAMPfmsmic-1 (n = 3) prostate tumor was
extracted as described above. 2 ug RNA from each sample was
reverse transcribed and subjected to qRT-PCR using the same
procedure and MIC-1/GDF15 primer set as above. TBP was
amplified as a housekeeping gene using primer set Forward: 59-
ACCCTTCACCAATGACTCCTATG-39 and Reverse: 59-AT-
GATGACTGCAGCAAATCGC-39. The specificity of the prod-
ucts was verified by melting curves generated by the Lightcycler
480 software Version 1.5 and by size on electrophoretic gels.
Relative ratio of MIC-1/GDF15 to TBP was then calculated using
Lightcycler 480 software Version 1.5.
Estimation of TC1-T5 TRAMP Lung Tumors
TRAMP C1 (TC1) is an androgen dependant PCa cell line
derived from TRAMP prostate tumor by Foster et al. [48]. TC1-
T5 is an androgen independent subline of TC1 cell line [49]. TC1-
T5 cells do not express MIC-1/GDF15 in culture and are thus
suitable to assess the effects of MIC-1/GDF15. TC1-T5 cells were
grown in DMEM media (Invitrogen, Life Technologies) contain-
ing 5% of charcoal dextran stripped fetal-calf serum and 125U/L
insulin (Humulin-BD Biosciences). To directly test whether TC1-
T5 cells would metastasise more in MIC-1fms mice, we injected
56105 cells in a total volume of 100 ml via the tail vein of 9-week-
old MIC-1fms (n = 17) and syngeneic C57BL/6 (n= 14) mice. Ten
weeks later, mice were sacrificed; their lungs were excised and
fixed in Bouin’s fixative (Sigma-Aldrich). Lung colonies on the
surface of all the lobes of both lungs were counted under a
dissecting microscope.
MIC-1/GDF15 and Prostate Cancer
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Statistical Analysis
Statistical evaluations of all the experiments were performed
with GraphPad Prism software version 5 (GraphPad Software, San
Diego, CA, USA). All the data are presented as the mean 6
standard error of the mean (SEM). Comparisons between groups
were made using unpaired t tests or Chi-square test as appropriate
and the two-tailed p values reported. Survival curves were
analyzed by Kaplan–Meier analysis and log-rank statistic is
reported. To examine the relationship of metastasis with survival
time we used multivariate analysis. All factors significantly
associated with metastasis by univariate regression were included
in a multivariate regression model with survival time. A p value
less than 0.05 considered statistically significant.
Results
Overexpression of MIC-1/GDF15 Prolongs PCa Survival in
TRAMP Mice
In order to assess the effects of MIC-1/GDF15 on the overall
survival of TRAMP mice, we monitored a cohort of TRAMP and
TRAMPfmsmic-1 mice till death or ethical end point. Kaplan-Meier
survival analysis showed that double transgenic TRAMPfmsmic-1
survived significantly longer than TRAMP mice (Fig. 1A,
p= 0.0002, log-rank test).
Initially, both TRAMP and TRAMPfmsmic-1 mice died at a
similar rate. However, after about 38-40 weeks, TRAMP mice
started to succumb faster than the TRAMPfmsmic-1 mice. The 50%
survival of 40 weeks in TRAMP mice was extended to 51 weeks in
the TRAMPfmsmic-1 group. Further, whilst only 9.4% of TRAMP
mice survived at week 50, 52% of TRAMPfmsmic-1 mice were still
alive (Fig. 1A). Over all, the average survival time for
TRAMPfmsmic-1 mice was 47.4 weeks and was 41 weeks for the
TRAMP mice. Thus, on average, TRAMPfmsmic-1 mice survived
approximately 7.4 weeks (,2 months) longer than the TRAMP
mice. These data indicate that increased expression of MIC-1/
GDF15 is able to substantially improve PCa related survival in
TRAMP mice.
Overexpression of MIC-1/GDF15 Restrains PCa Growth
To directly assess the impact of MIC-1/GDF15 on prostate
cancer growth, we assigned 60 TRAMP and 60 TRAMPfmsmic-1
mice at 4–6 weeks of age and culled them progressively
throughout 8–33 weeks of age. Comparisons were made using
the 15 mice pre-assigned to each group at the four different time
points (8, 17, 25 and 33 weeks), representing very early to
advanced tumor stages. Data from mice sacrificed at each time
point indicated that TRAMPfmsmic-1 mice had significantly smaller
GU complexes than TRAMP mice (Fig. 1B) at all stages
(p = 0.0004, p= 0.0005, p,0.0001, and p= 0.02, respectively).
When prostate and SV weights were analyzed separately from
the GU complex, SV tumor sizes were significantly reduced in
TRAMPfmsmic-1 mice at all time points (Fig. 1C). A similar, but
more varied, effect of MIC-1/GDF15 overexpression was
observed on prostate tumor growth (Fig. 1D). There was 17.0%
and 26% reduction in prostate tumor weight at weeks 8 and 25
respectively in TRAMPfmsmic-1 as compared to TRAMP mice
(p= 0.04 and 0.01, respectively). Although there was reduced
tumor weight in TRAMPfmsmic-1 mice at 17 weeks (.10%), the
difference between the two groups was not significant. At
33 weeks, although there was 55% reduction in the average
prostate weight in TRAMPfmsmic-1 mice compared with that in
TRAMP mice, the difference between the two groups was not
significant because of the large variation in the prostate tumor size
in the TRAMP group. Additional mice needed to be assigned to
this group as many of the originally assigned mice died/reached
ethical end point between 23 and 33 weeks, potentially biasing the
TRAMP results, by the selection of TRAMP mice with smaller
tumors. These mice with smaller tumors were more likely to
survive to 33 weeks of age and be selected. However, the data
suggested, consistent with the survival cohort data, that MIC-1/
GDF15 overexpression decreases tumor growth.
TRAMPfmsmic-1 Mice have Lower Grade Cancers
In addition to following the tumor growth, we determined
whether MIC-1/GDF15 might also affect PCa grade, by
comparing histopathological scores in TRAMP and double
transgenic TRAMPfmsmic-1 prostate tumors. At week 8, low (Grade
2) and high (Grade 3) grade PIN were the dominant pathologies in
TRAMP and TRAMPfmsmic-1 mice. Whilst the average proportion
of the prostate affected by PIN was higher in TRAMP compared
to TRAMPfmsmic-1 mice; however, this difference was not
statistically significant (Fig. 2A).
At week 17, Grade 2 and Grade 3 pathologies were still
dominant in both of the mouse lines but Grade 4, 5 and 6 tumors
started emerging in the TRAMP prostates. At this time point
TRAMP mice had significantly more Grade 3 disease (p,0.0001)
and significantly less Grade 2 disease (p,0.0001) than TRAMPfms-
mic-1 mice indicating more rapid tumor progression (Fig. 2B).
At 25 weeks of age, Grade 4 tumors were more prominent in
TRAMP mice but regions of Grade 2 and Grade 3 tumor were
still present in both mouse lines. Comparison between individual
tumor grades in the TRAMP and TRAMPfmsmic-1 prostate
showed that a higher percentage of the TRAMPfmsmic-1 prostate
had the lower Grades 2 and 3 tumors (p= 0.004 and 0.02,
respectively) whilst a significantly lower percentage of TRAMPfms-
mic-1 prostate had the more aggressive Grade 4 tumors (Fig. 2C,
p= 0.019).
By 33 weeks age (Fig. 2D), most of the mice, in both groups, had
advanced disease and the difference in the distribution of tumor
grades between the TRAMP and TRAMPfmsmic-1 mice was not
significant. Again these data may have been influenced by the
selection bias in the 33 weeks TRAMP group, discussed above.
Mice in the TRAMP group with more aggressive tumors died
prior to 33 weeks of age, and only mice with the less aggressive
tumors survived to this age. Overall, these data suggested that
TRAMPfmsmic-1 mice have a larger proportion of the prostate at a
lower tumor grade than TRAMP mice (Fig. 2A, B, C and D),
indicating the MIC-1/GDF15 overexpression slows local tumor
evolution.
TRAMP Prostate Lacks MIC-1/GDF15 Expression
In order to rule out the possibility that expression of MIC-1/
GDF15 by cancers in the TRAMP mice might impact upon tumor
growth and modify differences between them and mice engineered
to overexpress this cytokine, we quantified MIC-1/GDF15
expression in the prostate and seminal vesicle tumors from
TRAMP and TRAMPfmsmic-1 mice. Due to unavailability of an
established mouse MIC-1/GDF15 ELISA and a specific anti
mouse MIC-1/GDF15 monoclonal antibody, we used qRT-PCR
to compare the MIC-1/GDF15 expression in TRAMP and
TRAMPfmsmic-1 prostate and primary tumors. There was negligi-
ble MIC-1/GDF15 expression in TRAMP mice, which are wild
type for MIC-1/GDF15, at 8, 17 and 25 weeks of age (Fig. 3A)
and with advanced tumors (Fig. 3B). By contrast TRAMPfmsmic-1
mice expressed 44–166 fold more MIC-1/GDF15 (Fig. 3A) in
their prostate that is consistent with c-fms driven MIC-1/GDF15
transgene expression from infiltrating myeloid cells.
MIC-1/GDF15 and Prostate Cancer
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Whilst TRAMPfmsmic-1 Mice Live Longer they have More
Metastasis
Since metastasis is the major cause of death from solid tumors in
patients with PCa, we evaluated the effect of MIC-1/GDF15 on
incidence and extent of metastasis in TRAMP mice. Although
TRAMPfmsmic-1 mice live longer and have slower primary tumor
growth (Fig. 1 A, B, C and D), a significantly higher proportion of
these mice demonstrated organs with metastasis. 15 out of 30
(50%) TRAMPfmsmic-1 mice had distant organ metastasis com-
pared to 6 out of 30 (20%) of TRAMP mice (Fig. 4A). A
significantly higher proportion of TRAMPfmsmic-1 mice had
macroscopically detectible metastatic lesions in the liver, kidney
and rectum. Whilst the proportion of TRAMPfmsmic-1 mice with
surface lung tumors was also increased, this fell short of statistical
significance (Fig. 4A). Interestingly rectal metastases developed in
6 out of 30 TRAMPfmsmic-1 but not in any of the TRAMP mice
(Fig. 4A). There was no difference in lymph node weight (data not
shown), suggesting that lymphatic spread was not increased in
TRAMPfmsmic-1 mice. To ensure that the increase in the number
of metastasis was not solely due to increased survival times we
examined the data available by multivariate logistic regression.
This analysis confirmed that increase in metastasis was indepen-
dent of length of survival (p = 0.03; multivariate regression).
Further, it was notable that this occurred in the face of smaller
tumors and lower tumor grades at all stages of disease, suggesting
mechanisms independent of the effect of MIC-1/GDF15 on the
primary tumor.
To further ensure the accuracy of this data we examined a
further cohort of 59 TRAMP and 33 TRAMPfmsmic-1 mice, who
died or reached ethical endpoint between the ages of 18–40 week,
a time period over which both groups of mice were dying at
equivalent rates. We enlisted more TRAMP than TRAMPfmsmic-1
mice, to compensate for the lower rate of metastases in the former.
Over this period, almost 50% TRAMPfmsmic-1 developed metas-
tasis, which was significantly more that the 20% observed in
TRAMP mice (Fig. 4B, p,0.001, Chi-square test).
Figure 1. TRAMPfmsmic-1 mice survive longer and have smaller prostate tumors than TRAMP mice. Overall survival of individual mice
from birth to death is shown (panel A). The survival data for TRAMP (—m—) and TRAMPfmsmic-1 (—D—) mice were plotted using the Kaplan-Meier
method. The log-rank statistic for median survival time is shown. The genitourinary (GU), seminal vesicle (SV) and prostate tumor sizes in
TRAMPfmsmic-1 and TRAMP mice (n = 15/group) sacrificed at 8, 17, 25 and 33 weeks of age are shown in panel B, C and D. The GU (panel B), SV (panel
C) and prostate weights (panel D) are presented as mean mg weight/g body weight 6 SEM. p values are shown as *p,0.05; **p,0.01; ***p,0.001.
doi:10.1371/journal.pone.0043833.g001
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Figure 2. TRAMPfmsmic-1 prostate tumors have lower histological grades. Prostates of 15 TRAMP and 15 TRAMPfmsmic-1 mice were excised at
week 8 (panel A), 17 (panel B), 25 (panel C), and 33 (panel D). Serial sections were graded and scores for each grade were averaged for all the mice in
the group. The graph represents the mean proportion of the prostate from all the mice in the group having each different pathologic grade, scored
between 1 and 66 SEM. Numbers on the bars show number of mice in the group having a particular grade. p values are shown as *p,0.05;
**p,0.01; ***p,0.001.
doi:10.1371/journal.pone.0043833.g002
Figure 3. MIC-1/GDF15 expression in TRAMP and TRAMPfmsmic-1 prostate and TC1-T5 cell line. (A) MIC-1/GDF15 expression was quantified
by qRT-PCR in the prostate of TRAMP and TRAMPfmsmic-1 mice at 8, 17 and 25 weeks and normalized to B-actin expression as described in material
and methods. (B) Relative MIC-1/GDF15 expression was quantified by qRT-PCR in the TC1-T5 cell line (n = 3) and compared with TRAMP (n= 3) and
TRAMPfmsmic-1 (n = 3) prostate tumor after normalizing with TBP expression. Values are presented as mean normalizedMIC-1/GDF15 expression6SEM.
p values for the two-tailed unpaired t test are shown as ***p,0.001.
doi:10.1371/journal.pone.0043833.g003
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TC1-T5 TRAMP Cells Metastasise More Frequently in MIC-
1fms Mice
The increased metastases observed in TRAMPfmsmic-1 mice
might be due to various factors such as an increase in the number
of tumor stem cells, increased ability of tumor cells to invade the
vasculature or an enhanced capacity of blood born tumor cells to
adhere to, invade and grow in the metastatic target organ. As
TRAMPfmsmic-1 mice overexpress MIC-1/GDF15 systemically,
part of its prometastatic actions may relate to effects of this
cytokine on the vasculature of the target organ. To test if this
might be the case, we utilised the TRAMP TC1-T5 tumor cell
line. These cells, which are also of C57BL/6 mouse origin and
express no MIC-1/GDF15 (Fig. 3B), were injected intravenously
into MIC-1/GDF15 overexpressing MIC-1fms and syngeneic
C57BL/6 mice. Ten weeks later, TC1-T5 lung tumor colonies
were counted under a dissecting microscope. At an average of
76.3568.931 colonies, MIC-1fms mouse lungs, had almost 3 times
as many tumor colonies as control mice (24.2964.417 colonies,
Fig. 4C, p,0.0001). These data indicate that at least some of the
actions mediating MIC-1/GDF15 associated metastases are
independent of its actions on primary tumor cells themselves
and are likely to involve mechanisms such as increased tumor
vascular adhesion, survival or extravasation.
Discussion
This study relies on the use of the TRAMP PCa prone mouse.
In this spontaneous transgenic mouse model, the probasin (rPB)
regulatory sequence targets expression of SV40 early genes (T and
t; Tag) specifically to prostatic epithelium [44]. These mice
reproducibly develop PIN lesions with the onset of puberty, which
then progress in a very similar manner to human PCa, making it
an ideal model of early tumor development [47]. However, unlike
most human PCa, TRAMP PCas do not express MIC-1/GDF15,
perhaps due to the inhibition of p53, a major driver of MIC-1/
GDF15 expression, by the SV40 T antigen in the TRAMP
transgene [50–52]. Because of this, there is no background
expression of MIC-1/GDF15 in the TRAMP mouse seminal
vesicles or prostate to complicate the interpretation of local
prostate tumor development in TRAMPfmsmic-1 mice. In the MIC-
1fms mice that contributed the MIC-1/GDF15 transgene, consti-
tutive MIC-1/GDF15 overexpression occurs from myeloid cells
[33]. Thus, whilst not directly examined as part of this study, the
source of MIC-1/GDF15 overexpression in the prostates of
TRAMPfmsmic-1 mice would be expected to be the infiltrating or
tissue derived macrophages or dendritic cells known to be present
in prostate cancers. Additionally, this overexpression should raise
serum MIC-1/GDF15 levels in TRAMPfmsmic-1 mice as it does in
MIC-1fms mice [53]. Thus MIC-1/GDF15 could act both
systemically and/or directly on the prostate epithelial cells. This
is analogous to what would frequently occur in man. In human
PCa tumors, most MIC-1/GDF15 is expressed by malignant
epithelial cells [5,10] although there is also be a contribution from
Figure 4. MIC-1/GDF15 increases metastasis. (A) Comparison
between proportion of TRAMP (n= 30) and TRAMPfmsmic-1 (n = 30) mice
having distant organ metastasis. The data is analyzed by Chi-square
test. (B) Comparison between proportion of TRAMP (n = 59) and
TRAMPfmsmic-1 (n = 33) mice with metastasis at 18–40 weeks, a period
where TRAMP and TRAMPfmsmic-1 mice reach ethical end points at the
same rate. The data is analyzed by Chi-square test. (C) Comparison
between number of lung tumor colonies in MIC-1fms mice and control
C57BL/6 mice injected intravenously with TC1-T5 cells. The data is
analyzed by Unpaired t test. The p values for Chi-square test and
Unpaired t test are shown as ***p,0.001.
doi:10.1371/journal.pone.0043833.g004
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tumor stromal cells [11] and infiltrating phagocytes [12].
Additionally, all normal individuals have circulating levels of
MIC-1/GDF15 over a broad normal adult range of 150 to
1150 pg/ml [13]. These levels rise further, with aging, intercur-
rent diseases, pregnancy and in cancers. Some premalignant
lesions such as colonic adenomas, can also further increase serum
MIC-1/GDF15 levels [13].
There is a dearth of information about the effects of MIC-1/
GDF15 in spontaneous models of cancer development, which
more closely correspond to cancer biology in man. For MIC-1/
GDF15, the only other study in transgenic cancer models, have
been in the APCmin/+ small and large bowel polyp prone mice.
Consistent with our current data, mice systemically overexpressing
MIC-1/GDF15 were relatively protected from developing small
bowel polyps [54]. Additionally, MIC-1/GDF15 gene deleted,
APCmin/+ mice loose non-steroidal anti-inflammatory drug
(NSAID) induced chemoprevention of colonic neoplasia [55].
The latter findings are also reflected in human studies as NSAIDs
use leads to a rise in serum MIC-1/GDF15 levels that is associated
with protection from colonic polyposis [56].
Whilst MIC-1/GDF15 has a favorable impact on the growth of
primary tumors, its overexpression causes a major increase on the
proportion of mice with metastases. Whilst slower primary tumor
growth and more metastases, might seem counterintuitive, this can
occur because many aspects of metastasis are regulated indepen-
dently of tumor growth. This apparently paradoxical action is also
not unprecedented and is displayed by TGF-b, a distant relative of
MIC-1/GDF15 [57].
At least some of the causes of increased metastases in
TRAMPfmsmic-1 mice must be independent of any MIC-1/
GDF15 induced alteration to the primary tumor. The TC1-T5
TRAMP cell line, that makes no MIC-1/GDF15, when injected
intravenously, is far more metastatic into transgenic MIC1/
GDF15 overexpressing MIC-1fms mice than into syngeneic WT
mice. These results suggest actions on tumor cell adherence,
survival or invasion.
Overall, our results support an important role for MIC-1/
GDF15 in the regulation of growth and development of cancer in
the TRAMP PCa prone mice. TRAMPfmsmic-1 mice had a
significantly reduced tumor grades and primary tumor size. As a
major cause of death in the C57BL/6 TRAMP model is growth
and local invasion from the primary tumor, TRAMPfmsmic-1 mice
lived significantly longer, than control TRAMP mice. However,
independently of this increased survival, more TRAMPfmsmic-1
than TRAMP mice had metastatic deposits, suggesting that with
advanced tumors, MIC-1/GDF15 may facilitate haematogenous
spread. This view was further supported by our studies in which
intravenous TC1-T5 TRAMP cell line injections lead to
significantly more metastasis in MIC-1/GDF15 overexpressing
MIC-1fms mice compared with syngeneic control mice. MIC-1/
GDF15 facilitated metastasis formation, if applicable to human
PCa, may have implications for the cancer management, because
increase in MIC-1/GDF15 expression or serum levels may impact
on metastasis formation. MIC-1/GDF15 serum levels may rise
because of the physiological factors such as increasing age or
pregnancy, production by the cancer, cancer treatment, injury or
intercurrent diseases [4]. Most cancer therapeutic modalities
including surgery, radiotherapy and chemotherapy [6,7,51] may
induce MIC-1/GDF15 expression, which can be seen both in
cancer and non-cancer tissues. Thus it is possible that in addition
to its beneficial effects, anticancer therapy may sow the seeds of
metastatic recurrence.
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